These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33569002)

  • 1. A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men.
    Zhang H; Wang H; Wei H; Chen H; Liu J; Li C; Zhu X; Li X; Yu J; Zhou Y; Yang X; Wang Z; Wu M; Ding Y
    Front Pharmacol; 2020; 11():609522. PubMed ID: 33569002
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra
    Zhang H; Li X; Liu J; Li C; Wu M; Zhu X; Sun J; Fang M; Ding Y
    Ann Med; 2021 Dec; 53(1):375-383. PubMed ID: 33629921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA
    Cao G; Wang J; He J; Hu Y; Yang H; Que L; Gu X; Yu J; Wu X; Wu J; Fang W; He Q; Zhang J
    Front Pharmacol; 2023; 14():1111893. PubMed ID: 37081963
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial.
    Leng X; Leszczyński P; Jeka S; Liu SY; Liu H; Miakisz M; Gu J; Kilasonia L; Stanislavchuk M; Yang X; Zhou Y; Dong Q; Rezk M; Mitroiu M; Addison J; Zeng X
    Lancet Rheumatol; 2024 Jan; 6(1):e40-e50. PubMed ID: 38258678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects.
    Yang J; Lin L; Long Q; Zhang Q; Sun G; Zhou L; Wang Q; Zhu J; Li F; Hu W
    BioDrugs; 2022 May; 36(3):393-409. PubMed ID: 35594017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
    Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E
    Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects.
    Qian H; Cheng J; Gui Y; Wang W; Liang L; Zhu H; Wu Q; Ou M; Chen Q; Yu C; Jia J
    Clin Transl Sci; 2023 Sep; 16(9):1704-1712. PubMed ID: 37403258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.
    Fenwick S; Vekariya V; Patel R; Hajela P; Modi K; Kale P; Nath A
    Osteoporos Int; 2023 Jan; 34(1):179-188. PubMed ID: 36287230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.
    Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects.
    Zhang H; Li C; Liu J; Wu M; Li X; Zhu X; Li Q; Wang B; Mao Y; Ding Y; Jin Q
    Expert Opin Investig Drugs; 2021 Feb; 30(2):185-192. PubMed ID: 33306418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects.
    Zhang H; Chen H; Li X; Wu M; Zhu X; Li C; Liu J; Wei H; Hu Y; Wang J; Yang Y; Zhu X; Ding Y
    Front Pharmacol; 2021; 12():646171. PubMed ID: 34122068
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial.
    Schwabe C; Illes A; Ullmann M; Ghori V; Vincent E; Petit-Frere C; Monnet J; Racault AS; Wynne C
    Expert Rev Clin Immunol; 2022 May; 18(5):533-543. PubMed ID: 35354411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.
    Knight B; Rassam D; Liao S; Ewesuedo R
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):839-46. PubMed ID: 26984210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study.
    Schwabe C; Wynne C; Dyapa DR; Prajapati A; Dadke D
    Oncol Ther; 2024 Sep; 12(3):477-490. PubMed ID: 38972020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT-P47 and Reference Tocilizumab: A Randomized, Double-Blind, Phase 1 Study.
    Haranaka M; Eto T; Tanaka T; Yazawa R; Burmester G; Keystone E; Kim S; Bae Y; Suh J; Yang G; Kim Y; Lee J; Smolen JS
    J Clin Pharmacol; 2024 Oct; ():. PubMed ID: 39415551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
    Hyland E; Mant T; Vlachos P; Attkins N; Ullmann M; Roy S; Wagner V
    Br J Clin Pharmacol; 2016 Oct; 82(4):983-93. PubMed ID: 27285856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men.
    Singh I; Patel R; Patel A; Jose V
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):193-202. PubMed ID: 32627073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men.
    Zhang H; Liu T; Wu M; Wei H; Li C; Li X; Liu J; Chen H; Ding Y; Liu L
    Expert Opin Biol Ther; 2022 Feb; 22(2):179-186. PubMed ID: 33616478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects.
    Zhang H; Li Q; Zhu X; Li C; Li X; Liu C; Hu Y; Chen G; Wei H; Wang J; Shen Z; Ding Y
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):615-623. PubMed ID: 30043208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.
    Sinn A; García-Alvarado F; Gonzalez V; Huerga C; Bullo F
    Br J Clin Pharmacol; 2022 Mar; 88(3):1063-1073. PubMed ID: 34374114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.